statnews.com
Cure8 news brief
Why This Matters
People with Crohn’s disease who rely on local specialty pharmacies or critical access hospitals could be indirectly affected by 340B policy: pharmacies may lose money dispensing biologics that carry orphan designations for other diseases, which can threaten local access, pharmacy services, or convenience of in-person pickup.
The article highlights a policy debate—HRSA’s rebate pilot and the orphan-drug exclusion—that could change how these drugs are priced and reimbursed and thus affect where and how patients obtain biologic therapies.
Who Should Pay Attention
Crohn’s and IBD patients who use biologic or JAK inhibitor therapies, specialty pharmacists and hospital pharmacy managers, clinicians prescribing advanced therapies, policymakers interested in 340B and drug pricing, and patient advocates focused on access and affordability.
Study Snapshot
Story typeMainstream News
Evidence typeOpinion or Commentary
Source depthFull source text
What To Know
The article reports that because orphan status is tied to a drug molecule rather than the diagnosis, pharmacies that serve 340B-covered entities can be blocked from purchasing certain orphan-designated drugs at discounted prices even when those drugs are used for non-orphan conditions such as Crohn’s disease. HRSA’s new 340B rebate pilot (starting Jan.
1, 2027) would shift covered entities to buy at full price and seek rebates, and requires claims-level reporting; manufacturers may opt in and HRSA may expand the model.
The author emphasizes the financial strain on small critical access hospitals and specialty pharmacies, notes that tracking indication at dispensing is more feasible now than in 2013, and urges policy change so covered entities can retain discount benefits when drugs are used for common indications.
The piece is an opinion/advocacy column rather than original research or regulatory text. It cites past HRSA rules, court decisions, and a 2021 HHS OIG report to illustrate how small shares of use may be for orphan indications even when a drug has multiple approvals.
Keep In Mind
This is an opinion piece by a specialty pharmacist describing policy impacts and advocating for change; it summarizes regulatory history (HRSA rules, court rulings) and a pilot program announced by HRSA. It does not present new clinical data.
The article names Rinvoq (upadacitinib) as an example and discusses orphan designations for certain indications; readers should consult official HRSA materials or legal analyses for formal policy language and specifics about the pilot’s implementation and scope.
Source Details
Review the original publication for the complete reporting, methods, and context.
Publicationstatnews.com
Indexed viaGoogle News
Source typeWeb article
PublishedOct 2, 2026, 8:33 AM
Content availableFull source text
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Opinion: CT insurers deny adequate coverage for chronic illness - CT Mirror
High out-of-pocket costs and insurance practices can force people with Crohn’s and other chronic autoimmune diseases to delay or stop biologic therapy, which has direct consequences for disease control and quality of...
California Is One Vote Away from Affordable Medicine
This bill could make lower-cost biosimilars more available at the pharmacy counter, potentially reducing out-of-pocket costs and helping people with Crohn’s disease and other conditions stay on prescribed biologic...
These are the drugs that lose their U.S. patents in 2025: most are in common use across the country by millions of people
Patent expirations can allow biosimilars or generics to enter the U.S. market, which may lower costs and change which versions of IBD biologic drugs are available. Patients on affected medicines should be aware because...